Aspira Women's Health Inc.

$0.082 USD

-$0.02 (-15.9%)

Volume: 443.52K
Average Volume: 4.52M
Market Capitalization: $2.46M
P/E Ratio: -0.32
Dividend Yield: 0.00%
Price Target: $3.30

Year High: $3.63
Year Low: $0.08
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $0.68

Price Target and Rating

Average Stock Price Forecast	$3.30
High Stock Price Forecast	$3.30
Low Stock Price Forecast	$3.30
Forecast Upside/Downside	-97.52%
Consensus Rating	N/A
Rating Score(0-5)	0
Research Coverage	5 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$0.37
Trailing P/E Ratio	-0.32
PEG Ratio	0.00
P/E Growth	0.00
Net Income	-$12.78M
Net Margin	-115.13%
Pretax Margin	-115.13%
Return on Equity	203.31%
Return on Assets	-201.47%

Financials Score

AltmanZ Score	-146.90
Piotroski Score	1.00
Working Capital	-1.81M
Total Assets	5.09M
Ebit	1.84M
Market Cap	2.46M
Total Liabilities	11.3M

Company Executives

Name	Title
Michelle Snider	Senior Vice President of Commercial Strategy & Operations
Nicolette Possemato	Senior Vice President of Human Resources
Jamie L. Sullivan	Chief of Staff & ARPA-H Program Director

About Aspira Women's Health Inc. (NASDAQ:AWH) Stock

Aspira Women's Health Inc., alongside its subsidiaries, specializes in the development and commercialization of diagnostic tools for gynecologic diseases across the United States. Their product portfolio includes tests such as OVA1, OVERA, and OVA1plus, designed to evaluate the risk of ovarian malignancy in women presenting with adnexal masses. Additionally, they provide ASPiRA GenetiX, a genetic screening option for assessing individual susceptibility to gynecologic cancers. The company operates Aspira Synergy, a cloud-based platform enabling decentralized access to protein biomarker and hereditary genetic testing. Furthermore, Aspira owns and manages ASPiRA LABS, a specialized laboratory dedicated to applying advanced biomarker technologies for the management of gynecologic cancers and r ... elated conditions. Its innovation pipeline features upcoming products like OVAWatch, EndoCheck, and OVAInherit. Aspira serves a diverse clientele, including individual physicians, physician office laboratories, and both national and regional laboratory networks. The company actively collaborates with several institutions, holding a research agreement with Baylor Genetics and another with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to explore microRNA technology for enhanced early ovarian cancer detection. A strategic alliance is also in place with Quest Diagnostics, Incorporated. Incorporated in 1993 and headquartered in Austin, Texas, the company adopted its current name, Aspira Women's Health Inc., in June 2020, having previously operated as Vermillion, Inc.

AWH Announces Reverse Stock Split Vote in Support of Planned U.S. Exchange Uplisting

2026-07-13 08:00:00

Virtual Special Meeting of Stockholders to be held August 28, 2026 NEW YORK, July 13, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with a Special Meeting of Stockholders (the "Special Meeting") to approve a reverse stock split (the "Reverse Stock Split") of the Company's Class A common stock (the "Class A Common Shares"). "A reverse stock split is a necessary step on our path to a listing on a major U.S. exchange," said Sam Brill, CEO & Director of AWH.

AWH Files DEA Registration Applications for State-Licensed Medical Cannabis Operations

2026-06-30 08:00:00

NEW YORK, June 30, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced that it has filed applications with the U.S. Drug Enforcement Administration ("DEA") to register certain state-licensed medical cannabis operations under the expedited registration pathway established in connection with the rescheduling of medical marijuana to Schedule III of the Controlled Substances Act. "This is an important first step for medical cannabis patients and the medical community, while laying the groundwork for broader normalization across the industry," said Sam Brill, CEO & Director of AWH.

Aspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's Health

2026-05-26 09:02:00

Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, TX AND CLEVELAND, OH / ACCESS Newswire / May 26, 2026 / Aspira Women's Health Inc. (OTCQX:AWHL) ("Aspira" or the "Company"), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women's health, and Cleveland Clinic have signed an agreement to improve women's health diagnostics. Under the terms of this Master Collaboration and License Agreement, Aspira and Cleveland Clinic will collaborate on research projects focused on the discovery and validation of novel biomarker signatures and the development of advanced analytical models intended to improve diagnostic accuracy, clinical utility, and patient care.

AWH Reports First Quarter 2026 Financial Results

2026-05-13 16:00:00

Generated Q1 2026 net revenue of $116.9 million and Adjusted EBITDA1 of $26.3 million 51-location footprint to date, with five dispensaries added in 20262 Ranked No. 2 brand house in Illinois, Massachusetts, and New Jersey combined in Q1 20263 Rescheduling poised to unlock immediate and near-term benefits, with potential further impact from follow-on actions NEW YORK, May 13, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator and consumer packaged goods company, today reported its financial results for the quarter ended March 31, 2026 ("Q1 2026").

AWH to Hold First Quarter 2026 Earnings Conference Call on Wednesday, May 13, 2026

2026-04-29 08:00:00

NEW YORK, April 29, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH-U) (OTCQX: AAWH), a leading, multi-state, vertically integrated cannabis operator and consumer packaged goods company, today announced that it will hold a conference call on Wednesday, May 13, 2026, at 5:00 p.m. ET following the release of its first quarter 2026 financial results.

Frequently Asked Questions

What is the current Aspira Women's Health Inc. (AWH) stock price?: Aspira Women's Health Inc.(NASDAQ:AWH) stock price is $0.082 in the last trading session. During the trading session, AWH stock reached the peak price of $3.63 while $0.08 was the lowest point it dropped to. The percentage change in AWH stock occurred in the recent session was --15.9% while the dollar amount for the price change in AWH stock was -$0.02.
AWH's industry and sector of operation?: The NASDAQ listed AWH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
Who are the executives of AWH?: Michelle Snider | Senior Vice President of Commercial Strategy & Operations
Nicolette Possemato | Senior Vice President of Human Resources
Jamie L. Sullivan | Chief of Staff & ARPA-H Program Director
|
|
How many employees does AWH have?: Number of AWH employees currently stands at 66. AWH operates from Building III, Austin, TX 78738, US.

Link for AWH official website?: Official Website of AWH is: https://aspirawh.com
How do I contact AWH?: AWH could be contacted at phone #512 519 0400 and can also be accessed through its website. AWH operates from Building III, Austin, TX 78738, US.
How many shares of AWH are traded daily?: The average number of AWH shares traded daily for last 3 months was 4.52M.
What is the market cap of AWH currently?: The market value of AWH currently stands at $2.46M with its latest stock price at $0.082

Enter your email address below for free access to our Aspira Women's Health Inc. (AWH) research center and poll results.

Aspira Women's Health Inc.

$0.082 USD

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Financial Health Scores

Key Metrics (TTM)

Company Executives

Poll Results